184 related articles for article (PubMed ID: 26668337)
1. Developing Outcomes Assessments as Endpoints for Registrational Clinical Trials of Antibacterial Drugs: 2015 Update From the Biomarkers Consortium of the Foundation for the National Institutes of Health.
Talbot GH; Powers JH; Hoffmann SC;
Clin Infect Dis; 2016 Mar; 62(5):603-7. PubMed ID: 26668337
[TBL] [Abstract][Full Text] [Related]
2. Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes of Health.
Talbot GH; Powers JH; Fleming TR; Siuciak JA; Bradley J; Boucher H;
Clin Infect Dis; 2012 Oct; 55(8):1114-21. PubMed ID: 22744885
[TBL] [Abstract][Full Text] [Related]
3. A collaborative model for endpoint development for acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia.
Toerner JG; Burke L; Komo S; Papadopoulos E
Clin Infect Dis; 2012 Oct; 55(8):1122-3. PubMed ID: 22744886
[No Abstract] [Full Text] [Related]
4. Improving Conduct and Feasibility of Clinical Trials to Evaluate Antibacterial Drugs to Treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia: Recommendations of the Clinical Trials Transformation Initiative Antibacterial Drug Development Project Team.
Knirsch C; Alemayehu D; Botgros R; Comic-Savic S; Friedland D; Holland TL; Merchant K; Noel GJ; Pelfrene E; Reith C; Santiago J; Tiernan R; Tenearts P; Goldsack JC; Fowler VG
Clin Infect Dis; 2016 Aug; 63 Suppl 2():S29-36. PubMed ID: 27481950
[TBL] [Abstract][Full Text] [Related]
5. FDA guidance for ABSSSI trials: implications for conducting and interpreting clinical trials.
Itani KM; Shorr AF
Clin Infect Dis; 2014 Jan; 58 Suppl 1():S4-9. PubMed ID: 24343831
[TBL] [Abstract][Full Text] [Related]
6. New rules for clinical trials of patients with acute bacterial skin and skin-structure infections: do not let the perfect be the enemy of the good.
Corey GR; Stryjewski ME
Clin Infect Dis; 2011 Jun; 52 Suppl 7():S469-76. PubMed ID: 21546623
[TBL] [Abstract][Full Text] [Related]
7. Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
Lodise TP; Low DE
Drugs; 2012 Jul; 72(11):1473-93. PubMed ID: 22779432
[TBL] [Abstract][Full Text] [Related]
8. Clinical Outcome Assessments: Conceptual Foundation-Report of the ISPOR Clinical Outcomes Assessment - Emerging Good Practices for Outcomes Research Task Force.
Walton MK; Powers JH; Hobart J; Patrick D; Marquis P; Vamvakas S; Isaac M; Molsen E; Cano S; Burke LB;
Value Health; 2015 Sep; 18(6):741-52. PubMed ID: 26409600
[TBL] [Abstract][Full Text] [Related]
9. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
10. Clinician-reported lesion measurements in skin infection trials: Definitions, reliability, and association with patient-reported pain.
Powers JH; Das AF; De Anda C; Prokocimer P
Contemp Clin Trials; 2016 Sep; 50():265-72. PubMed ID: 27530088
[TBL] [Abstract][Full Text] [Related]
11. Exploration of a Potential Desirability of Outcome Ranking Endpoint for Complicated Intra-Abdominal Infections Using 9 Registrational Trials for Antibacterial Drugs.
Kinamon T; Gopinath R; Waack U; Needles M; Rubin D; Collyar D; Doernberg SB; Evans S; Hamasaki T; Holland TL; Howard-Anderson J; Chambers H; Fowler VG; Nambiar S; Kim P; Boucher HW
Clin Infect Dis; 2023 Aug; 77(4):649-656. PubMed ID: 37073571
[TBL] [Abstract][Full Text] [Related]
12. Recommended design features of future clinical trials of antibacterial agents for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
; ; ; ; Spellberg B; Talbot G
Clin Infect Dis; 2010 Aug; 51 Suppl 1(Suppl 1):S150-70. PubMed ID: 20597666
[No Abstract] [Full Text] [Related]
13. Exploration of a Potential DOOR Endpoint for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Using Six Registrational Trials for Antibacterial Drugs.
Kinamon T; Waack U; Needles M; Rubin D; Collyar D; Doernberg SB; Evans SR; Hamasaki T; Holland TL; Howard-Anderson J; Chambers H; Fowler VG; Nambiar S; Kim P; Boucher HW; Gopinath R
Clin Infect Dis; 2024 Mar; ():. PubMed ID: 38527855
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of ceftobiprole in patients aged 65 years or older: a
Welte T; Scheeren TW; Overcash JS; Saulay M; Engelhardt M; Hamed K
Future Microbiol; 2021 May; 16():543-555. PubMed ID: 33960817
[TBL] [Abstract][Full Text] [Related]
15. Streamlining Safety Data Collection in Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Trials: Recommendations of the Clinical Trials Transformation Initiative Antibacterial Drug Development Project Team.
Donnelly H; Alemayehu D; Botgros R; Comic-Savic S; Eisenstein B; Lorenz B; Merchant K; Pelfrene E; Reith C; Santiago J; Tiernan R; Wunderink R; Tenaerts P; Knirsch C
Clin Infect Dis; 2016 Aug; 63 Suppl 2():S39-45. PubMed ID: 27481952
[TBL] [Abstract][Full Text] [Related]
16. Systematic Review and Meta-Analysis To Estimate Antibacterial Treatment Effect in Acute Bacterial Skin and Skin Structure Infection.
Cates JE; Mitrani-Gold FS; Li G; Mundy LM
Antimicrob Agents Chemother; 2015 Aug; 59(8):4510-20. PubMed ID: 25987628
[TBL] [Abstract][Full Text] [Related]
17. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.
Corey GR; Good S; Jiang H; Moeck G; Wikler M; Green S; Manos P; Keech R; Singh R; Heller B; Bubnova N; O'Riordan W;
Clin Infect Dis; 2015 Jan; 60(2):254-62. PubMed ID: 25294250
[TBL] [Abstract][Full Text] [Related]
18. Understanding Early and Late Endpoints in Registrational Trials of Community-acquired Bacterial Pneumonia.
Talbot GH
Clin Infect Dis; 2021 Nov; 73(9):e2613-e2615. PubMed ID: 32584958
[No Abstract] [Full Text] [Related]
19. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.
Zhanel GG; Love R; Adam H; Golden A; Zelenitsky S; Schweizer F; Gorityala B; Lagacé-Wiens PR; Rubinstein E; Walkty A; Gin AS; Gilmour M; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2015 Feb; 75(3):253-70. PubMed ID: 25673021
[TBL] [Abstract][Full Text] [Related]
20. Moving Beyond Mortality: Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia.
Howard-Anderson J; Hamasaki T; Dai W; Collyar D; Rubin D; Nambiar S; Kinamon T; Leister-Tebbe H; Hill C; Geres H; Holland TL; Doernberg SB; Chambers HF; Fowler VG; Evans SR; Boucher HW;
Clin Infect Dis; 2024 Feb; 78(2):259-268. PubMed ID: 37740559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
